CIDeRplusGeneral Information:
| Id: | 8,380 |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Fatty liver disease, nonalcoholic Insulin resistance |
| Homo sapiens | |
| article | |
| Reference: | Kalhan SC et al.(2011) Plasma metabolomic profile in nonalcoholic fatty liver disease Metab. Clin. Exp. 60: 404-413 [PMID: 20423748] |
Interaction Information:
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. There was a four-fold increase in the plasma concentration of glycocholate and taurocholate, and a two-fold increase in glycochenodeoxycholate in subjects with NASH as compared with controls. These bile acids were also higher in steatosis group compared with controls, however only taurocholate met the statistical significance cutoff. |
|
Formal Description Interaction-ID: 85059 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. There was a four-fold increase in the plasma concentration of glycocholate and taurocholate, and a two-fold increase in glycochenodeoxycholate in subjects with NASH as compared with controls. These bile acids were also higher in steatosis group compared with controls, however only taurocholate met the statistical significance cutoff. |
|
Formal Description Interaction-ID: 85299 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. There was a four-fold increase in the plasma concentration of glycocholate and taurocholate, and a two-fold increase in glycochenodeoxycholate in subjects with NASH as compared with controls. These bile acids were also higher in steatosis group compared with controls, however only taurocholate met the statistical significance cutoff. |
|
Formal Description Interaction-ID: 85300 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. There was a four-fold increase in the plasma concentration of glycocholate and taurocholate, and a two-fold increase in glycochenodeoxycholate in subjects with NASH as compared with controls. These bile acids were also higher in steatosis group compared with controls, however only taurocholate met the statistical significance cutoff. |
|
Formal Description Interaction-ID: 85301 |
phenotype increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85302 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85303 |
phenotype decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85304 |
phenotype decreases_quantity of drug/chemical compound Cysteineglutathione disulfide |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85305 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound Cysteineglutathione disulfide |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85306 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound Glu-Val |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85307 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85308 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound Glu-Leu |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85309 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85310 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound Glu-Phe |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85311 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85312 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound Glu-Tyr |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Consistent with decreased plasma glutathione in subjects with steatosis and NASH, the concentration of cysteine-glutathione disulfide, a product of glutathione and cysteine conjugate, was significantly lower in subjects with steatosis and NASH. Several glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine were higher in both NASH and steatosis. The increase was of similar magnitude in both groups. |
|
Formal Description Interaction-ID: 85313 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Several free fatty acids eicosapentaenoate (C20:5n3), docosahexaenoate (C22:6n3), 10-undecenoate (C11:1n1) and arachidonate (C20:4n6), were significantly lower in individuals with NASH as compared with controls. In contrast, only caprate (C10:0) and 10-undecenoate (C11:1n1) were significantly lower in subjects with steatosis as compared with controls. Only linolenate (C18:3n3 or 6) and undecanoate (C11:0) were significantly higher in subjects with steatosis when compared with those with NASH. |
|
Formal Description Interaction-ID: 85314 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Several free fatty acids eicosapentaenoate (C20:5n3), docosahexaenoate (C22:6n3), 10-undecenoate (C11:1n1) and arachidonate (C20:4n6), were significantly lower in individuals with NASH as compared with controls. In contrast, only caprate (C10:0) and 10-undecenoate (C11:1n1) were significantly lower in subjects with steatosis as compared with controls. Only linolenate (C18:3n3 or 6) and undecanoate (C11:0) were significantly higher in subjects with steatosis when compared with those with NASH. |
|
Formal Description Interaction-ID: 85315 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Several free fatty acids eicosapentaenoate (C20:5n3), docosahexaenoate (C22:6n3), 10-undecenoate (C11:1n1) and arachidonate (C20:4n6), were significantly lower in individuals with NASH as compared with controls. In contrast, only caprate (C10:0) and 10-undecenoate (C11:1n1) were significantly lower in subjects with steatosis as compared with controls. Only linolenate (C18:3n3 or 6) and undecanoate (C11:0) were significantly higher in subjects with steatosis when compared with those with NASH. |
|
Formal Description Interaction-ID: 85316 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound 10-Undecenoate |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Several free fatty acids eicosapentaenoate (C20:5n3), docosahexaenoate (C22:6n3), 10-undecenoate (C11:1n1) and arachidonate (C20:4n6), were significantly lower in individuals with NASH as compared with controls. In contrast, only caprate (C10:0) and 10-undecenoate (C11:1n1) were significantly lower in subjects with steatosis as compared with controls. Only linolenate (C18:3n3 or 6) and undecanoate (C11:0) were significantly higher in subjects with steatosis when compared with those with NASH. |
|
Formal Description Interaction-ID: 85317 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Several free fatty acids eicosapentaenoate (C20:5n3), docosahexaenoate (C22:6n3), 10-undecenoate (C11:1n1) and arachidonate (C20:4n6), were significantly lower in individuals with NASH as compared with controls. In contrast, only caprate (C10:0) and 10-undecenoate (C11:1n1) were significantly lower in subjects with steatosis as compared with controls. Only linolenate (C18:3n3 or 6) and undecanoate (C11:0) were significantly higher in subjects with steatosis when compared with those with NASH. |
|
Formal Description Interaction-ID: 85318 |
phenotype decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Several free fatty acids eicosapentaenoate (C20:5n3), docosahexaenoate (C22:6n3), 10-undecenoate (C11:1n1) and arachidonate (C20:4n6), were significantly lower in individuals with NASH as compared with controls. In contrast, only caprate (C10:0) and 10-undecenoate (C11:1n1) were significantly lower in subjects with steatosis as compared with controls. Only linolenate (C18:3n3 or 6) and undecanoate (C11:0) were significantly higher in subjects with steatosis when compared with those with NASH. |
|
Formal Description Interaction-ID: 85319 |
phenotype decreases_quantity of drug/chemical compound 10-Undecenoate |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Free carnitine and butyrylcarnitine levels were significantly elevated in both steatosis and NASH compared with controls. In addition, propionylcarnitine and 2-methylbutyroylcarnitine levels were significantly higher in subjects with NASH only. |
|
Formal Description Interaction-ID: 85320 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Free carnitine and butyrylcarnitine levels were significantly elevated in both steatosis and NASH compared with controls. In addition, propionylcarnitine and 2-methylbutyroylcarnitine levels were significantly higher in subjects with NASH only. |
|
Formal Description Interaction-ID: 85321 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Free carnitine and butyrylcarnitine levels were significantly elevated in both steatosis and NASH compared with controls. In addition, propionylcarnitine and 2-methylbutyroylcarnitine levels were significantly higher in subjects with NASH only. |
|
Formal Description Interaction-ID: 85322 |
phenotype increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Free carnitine and butyrylcarnitine levels were significantly elevated in both steatosis and NASH compared with controls. In addition, propionylcarnitine and 2-methylbutyroylcarnitine levels were significantly higher in subjects with NASH only. |
|
Formal Description Interaction-ID: 85323 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Free carnitine and butyrylcarnitine levels were significantly elevated in both steatosis and NASH compared with controls. In addition, propionylcarnitine and 2-methylbutyroylcarnitine levels were significantly higher in subjects with NASH only. |
|
Formal Description Interaction-ID: 85324 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Free carnitine and butyrylcarnitine levels were significantly elevated in both steatosis and NASH compared with controls. In addition, propionylcarnitine and 2-methylbutyroylcarnitine levels were significantly higher in subjects with NASH only. |
|
Formal Description Interaction-ID: 85325 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound 2-Methylbutyroylcarnitine |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Significant differences in the levels of lysophosphocholines were observed between individuals with NASH and controls. Specifically, the concentration of glycerophosphocholine, 1-oleoylglycerophosphocholine, 1-linoleoylglycerophosphocholine and 1-arachidonoylglycerophosphocholine were significantly lower in NASH when compared with controls. Only 1-oleoylglycerophosphocholine was significantly lower in subjects with steatosis. |
|
Formal Description Interaction-ID: 85326 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Significant differences in the levels of lysophosphocholines were observed between individuals with NASH and controls. Specifically, the concentration of glycerophosphocholine, 1-oleoylglycerophosphocholine, 1-linoleoylglycerophosphocholine and 1-arachidonoylglycerophosphocholine were significantly lower in NASH when compared with controls. Only 1-oleoylglycerophosphocholine was significantly lower in subjects with steatosis. |
|
Formal Description Interaction-ID: 85328 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound LysoPC(18:1) |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Significant differences in the levels of lysophosphocholines were observed between individuals with NASH and controls. Specifically, the concentration of glycerophosphocholine, 1-oleoylglycerophosphocholine, 1-linoleoylglycerophosphocholine and 1-arachidonoylglycerophosphocholine were significantly lower in NASH when compared with controls. Only 1-oleoylglycerophosphocholine was significantly lower in subjects with steatosis. |
|
Formal Description Interaction-ID: 85330 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound LysoPC(18:2) |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Significant differences in the levels of lysophosphocholines were observed between individuals with NASH and controls. Specifically, the concentration of glycerophosphocholine, 1-oleoylglycerophosphocholine, 1-linoleoylglycerophosphocholine and 1-arachidonoylglycerophosphocholine were significantly lower in NASH when compared with controls. Only 1-oleoylglycerophosphocholine was significantly lower in subjects with steatosis. |
|
Formal Description Interaction-ID: 85332 |
disease Steatohepatitis, nonalcoholic decreases_quantity of drug/chemical compound LysoPC(20:4) |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Significant differences in the levels of lysophosphocholines were observed between individuals with NASH and controls. Specifically, the concentration of glycerophosphocholine, 1-oleoylglycerophosphocholine, 1-linoleoylglycerophosphocholine and 1-arachidonoylglycerophosphocholine were significantly lower in NASH when compared with controls. Only 1-oleoylglycerophosphocholine was significantly lower in subjects with steatosis. |
|
Formal Description Interaction-ID: 85333 |
phenotype decreases_quantity of drug/chemical compound LysoPC(18:1) |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Glucose and pyruvate were significantly higher in subjects with NASH. Mannose and lactate levels were higher in both steatosis and NASH. In addition, erythronate levels were higher in NAFLD subjects. |
|
Formal Description Interaction-ID: 85335 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Glucose and pyruvate were significantly higher in subjects with NASH. Mannose and lactate levels were higher in both steatosis and NASH. In addition, erythronate levels were higher in NAFLD subjects. |
|
Formal Description Interaction-ID: 85336 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Glucose and pyruvate were significantly higher in subjects with NASH. Mannose and lactate levels were higher in both steatosis and NASH. In addition, erythronate levels were higher in NAFLD subjects. |
|
Formal Description Interaction-ID: 85337 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Glucose and pyruvate were significantly higher in subjects with NASH. Mannose and lactate levels were higher in both steatosis and NASH. In addition, erythronate levels were higher in NAFLD subjects. |
|
Formal Description Interaction-ID: 85338 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Glucose and pyruvate were significantly higher in subjects with NASH. Mannose and lactate levels were higher in both steatosis and NASH. In addition, erythronate levels were higher in NAFLD subjects. |
|
Formal Description Interaction-ID: 85339 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Glucose and pyruvate were significantly higher in subjects with NASH. Mannose and lactate levels were higher in both steatosis and NASH. In addition, erythronate levels were higher in NAFLD subjects. |
|
Formal Description Interaction-ID: 85340 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Glucose and pyruvate were significantly higher in subjects with NASH. Mannose and lactate levels were higher in both steatosis and NASH. In addition, erythronate levels were higher in NAFLD subjects. |
|
Formal Description Interaction-ID: 85341 |
disease Fatty liver disease, nonalcoholic increases_quantity of drug/chemical compound Erythronic acid |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85342 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85343 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85344 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85345 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85346 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85347 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85348 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85349 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85350 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85351 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese, were insulin resistant. Among the essential amino acids, phenylalanine and branched chain amino acids, leucine, isoleucine, and valine were higher in subjects with NASH as compared with controls. Glutamate, aspartate and tyrosine were also elevated in individuals with NASH. In contrast to subjects with NASH, only glutamate, lysine, tyrosine and isoleucine were significantly higher in subjects with steatosis compared with controls. There were no significant differences in amino acid levels amongst subjects with steatosis and NASH. |
|
Formal Description Interaction-ID: 85352 |
|
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese and were insulin resistant. A number of unnamed biochemicals in the plasma were significantly higher in NAFLD subjects, in particular x-11546 and x-11529, which were almost 3-fold higher in NASH compared with controls. |
|
Formal Description Interaction-ID: 85353 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound X-11546 |
| Comment | The plasma profile of subjects with nonalcoholic fatty liver disease (NAFLD), steatosis, and steatohepatitis (NASH) was examined using an untargeted global metabolomic analysis to identify specific disease-related patterns and to identify potential noninvasive biomarkers. Plasma samples were obtained after an overnight fast from histologically confirmed nondiabetic subjects with hepatic steatosis (n = 11) or NASH (n = 24) and were compared with healthy, age- and sex-matched controls (n = 25). Subjects with NAFLD were obese and were insulin resistant. A number of unnamed biochemicals in the plasma were significantly higher in NAFLD subjects, in particular x-11546 and x-11529, which were almost 3-fold higher in NASH compared with controls. |
|
Formal Description Interaction-ID: 85354 |
disease Steatohepatitis, nonalcoholic increases_quantity of drug/chemical compound X-11529 |